

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/063966 A1

(51) International Patent Classification:

C07K 14/725 (2006.01) A61K 35/17 (2015.01)
C07K 14/47 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2021/076324

(22) International Filing Date:

24 September 2021 (24.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20198096.8 24 September 2020 (24.09.2020) EP

(71) Applicant: **MEDIGENE IMMUNOTHERAPIES
GMBH** [DE/DE]; Lochhamer Straße 11, 82152 Planegg-
Martinsried (DE).

(72) Inventors: **WEHNER, Carina**; Helene-Mayer-Ring
12, 80809 München (DE). **LONGINOTTI, Giulia**;
Christrosenweg 8, 81377 München (DE).

(74) Agent: **MAIWALD PATENTANWALTS- UND
RECHTSANWALTSGESELLSCHAFT MBH**; Dr. An-
nelie Wünsche, Elisenhof, Elisenstraße 3, 80335 München
(DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF




Figure 2

(57) Abstract: The present invention relates to a T cell receptor (TCR) capable of binding to a polypeptide comprising the amino acid sequence LYVDSLFFL, or a portion thereof, or its HLA-A bound form. The present invention further relates to nucleic acid molecules encoding said TCR, a vector comprising said nucleic acid molecule, as well as a host cell comprising said nucleic acid molecule or vector. The present invention further relates to methods for obtaining said TCR and to pharmaceutical and diagnostic compositions comprising said TCR, said nucleic acid molecule, vector, and/or host cell. The present invention further relates to such pharmaceutical and diagnostic compositions for use in diagnosing, detecting, preventing, and/or treating cancer. Furthermore, the present invention relates to the use of said TCR, nucleic acid molecule, or said vector, for generating modified lymphocytes.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))